Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

ADHD: To medicate or not

Iris K. Lesser, MD
Conditions
February 27, 2014
Share
Tweet
Share

When someone asks me what a developmental pediatrician does, I tell him or her that I treat children who have a variety of developmental problems, such as attention deficit hyperactivity disorder (ADHD). Without fail, that disclosure elicits some sort of an emotional reaction.

Many people have strong opinions about whether the disorder really exists. Parents are still being told, by family and so-called friends, that it’s “their fault,” and that all these children need is discipline, sometimes defined as “a swift kick in the you-know-what.”

The truth is that ADHD exists and often requires a multipronged approach to treatment. According to the CDC, 6.4 million children ages 4–17 have been diagnosed with ADHD in the U.S. This percentage has risen sharply over the past decade — from 7.8 percent in 2003 to 11 percent in 2011.

To medicate or not

Even more emotionally laden is the topic of medication. People tend to be either for or against stimulant medications, such as Ritalin and Adderall, with no middle ground. Earlier in my career, I had a charming but extremely hyperactive patient whose mother was a healthcare worker. After a variety of nondrug approaches failed to help her child, she finally resigned herself to starting a trial of medication, but just for when the child was in school. It worked well, but at a follow-up visit the mother, shamefaced, admitted that she had been giving her daughter the medication on weekends, as well as for school, after the girl tearfully asked “Can I please take my medication for soccer?”

A pivotal research project changed the treatment landscape. In 1999, the MTA Cooperative group published the Multimodal Treatment Study for Children with ADHD. This landmark study proved that medication, with or without behavioral treatment, was superior to community treatment or behavioral treatment alone.

The findings took the country by storm. Pharmaceutical executives happily embraced these powerful, scientifically based results that would enhance company market share and increase profits and dividends. Insurance company executives were equally excited, with no more need to pay for time-consuming and expensive behavioral interventions. I was ambivalent. On one hand, these were beneficial data to help convince reluctant parents of children with such severe ADHD that they weren’t benefitting from behavioral and academic interventions simply to try the medication. On the other hand, I knew that ADHD is a complex disorder that generally coexists with a number of other problems, and that, despite the results of the study, quick fixes are rarely a total solution.

Fifteen years later: Questions remain about the value of ADHD drugs

Fast forward to today: I am not surprised to read and hear that people, both healthcare professionals and others, question the validity of the MTA study and are reevaluating the impact it has had on the current generation of children with ADHD. People are blaming the study for the overuse of medication. However, now, instead of parents being told that they are responsible for their children’s problems, critics are suggesting that medication is being used to keep children quiet in the classrooms because teachers can’t control the children’s behavior.

I am still ambivalent. I believe that the questioning is good, because maybe it will cause more doctors to follow the revised and updated 2001 AAP guidelines for the multidisciplinary assessment and multimodal (medical, behavioral and educational) treatment of ADHD (AAP 2011; AAP 2001). Those guidelines emphasize the benefits of an integrated approach that combines drug and nondrug therapies. But I am concerned that media hype focusing on overuse rather than misuse of medication can lead to mass hysteria, like that seen with regard to autism and vaccinations. Given the nationwide prevalence of ADHD, ranging from 4.2 percent in Nevada to 14.8 percent in Kentucky (CDC, 2011), it is important that we not “throw the baby out with the bath water” by negating the value of medication as an integral part of a treatment plan. We cannot return to the dark ages.

ADHD drugs: Tools, not a panacea

In my professional opinion — after treating hundreds of ADHD cases since the 1990s — medication is a tool that allows many children with ADHD to benefit from other educational, behavioral and psychological treatments and thus function better in their lives. It’s not for everyone, and is not a magic bullet, but for children who have been appropriately diagnosed, it can mean the difference between success and failure.

Iris K. Lesser is an assistant professor, department of pediatrics (child development), Albert Einstein College of Medicine.  She blogs at The Doctor’s Tablet.

Prev

Framing an ethical dilemma: 4 basic concepts of medical ethics

February 26, 2014 Kevin 32
…
Next

To every cancer patient: You give us courage

February 27, 2014 Kevin 2
…

ADVERTISEMENT

Tagged as: ADHD, Pediatrics

Post navigation

< Previous Post
Framing an ethical dilemma: 4 basic concepts of medical ethics
Next Post >
To every cancer patient: You give us courage

ADVERTISEMENT

Related Posts

  • Concerns about the generic formulations of ADHD medications

    Jolene Won
  • A physician’s addiction to social media

    Amanda Xi, MD
  • How to spark the attention of patients

    Jamie Katuna
  • Students shouldn’t take Adderall as a study aid

    Roy Benaroch, MD
  • How this medical student is inspired by pediatrics

    Manar Mohammad, MD
  • Cutting the red tape with buprenorphine treatment for opioid use disorder

    Christina Kinnevey, MD

More in Conditions

  • Facing terminal cancer as a doctor and mother

    Kelly Curtin-Hallinan, DO
  • Why doctors must stop ignoring unintentional weight loss in patients with obesity

    Samantha Malley, FNP-C
  • Why hospitals are quietly capping top doctors’ pay

    Dennis Hursh, Esq
  • Why point-of-care ultrasound belongs in emergency department triage

    Resa E. Lewiss, MD and Courtney M. Smalley, MD
  • Why PSA levels alone shouldn’t define your prostate cancer risk

    Martina Ambardjieva, MD, PhD
  • Reframing chronic pain and dignity: What a pain clinic teaches us about MAiD and chronic suffering

    Olumuyiwa Bamgbade, MD
  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • America’s ER crisis: Why the system is collapsing from within

      Kristen Cline, BSN, RN | Conditions
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Beyond burnout: Understanding the triangle of exhaustion [PODCAST]

      The Podcast by KevinMD | Podcast
    • Facing terminal cancer as a doctor and mother

      Kelly Curtin-Hallinan, DO | Conditions
    • Online eye exams spark legal battle over health care access

      Joshua Windham, JD and Daryl James | Policy
    • FDA delays could end vital treatment for rare disease patients

      G. van Londen, MD | Meds
    • Pharmacists are key to expanding Medicaid access to digital therapeutics

      Amanda Matter | Meds
    • Why ADHD in women requires a new approach [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 6 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • America’s ER crisis: Why the system is collapsing from within

      Kristen Cline, BSN, RN | Conditions
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Beyond burnout: Understanding the triangle of exhaustion [PODCAST]

      The Podcast by KevinMD | Podcast
    • Facing terminal cancer as a doctor and mother

      Kelly Curtin-Hallinan, DO | Conditions
    • Online eye exams spark legal battle over health care access

      Joshua Windham, JD and Daryl James | Policy
    • FDA delays could end vital treatment for rare disease patients

      G. van Londen, MD | Meds
    • Pharmacists are key to expanding Medicaid access to digital therapeutics

      Amanda Matter | Meds
    • Why ADHD in women requires a new approach [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

ADHD: To medicate or not
6 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...